Equianalgesia, opioid switch and opioid association in different clinical settings: a narrative review.

Emergency or postoperative pain often represents an authentic challenge in patients who were already on opioid treatment for chronic pain. Thus, their management requires not only the physician's ability to treat acute pain, but also competence in switching the opioid that lost efficacy. Different aspects should be considered, such as opioids titration, switching, association and equianalgesia. The objective of this paper is to provide a narrative review, which has been elaborated and discussed among clinicians through an iterative process involving development and review of the draft during two web-based meetings and via email. This expert opinion aims to facilitate the correct opioid use through appropriate practices with a focus on pain treatment in emergency and postoperative pain. Equianalgesia tables were reviewed and integrated by clinicians and researchers with expertise in anesthesia, postoperative medicine, intensive care, emergency medicine pharmacology and addiction medicine. Special populations (liver/kidney failure, elder, pediatric, pregnancy/lactation) are discussed in detail along with other critical scenarios, such as: (i) rapid pain worsening in chronic pain (aggravating pain due to disease progression or tolerance development to analgesic therapy); (ii) acute pain on maintenance treatment; and (iii) pain management of complicated patients in emergency care. Extended and updated equianalgesia tables and conversion rates for 17 different opioid formulations (of 9 different molecules) are presented as follows. Opioids remain the class that best suits clinical needs of emergency and post-operative medicine. However, it should be stressed that equianalgesia can be affected by drug-to-drug interactions and pharmacological imprecision, in a complex field where clinical experience may be the main guiding principle.

[1]  H. Jones,et al.  Trends in Opioid and Psychotropic Prescription in Pregnancy in the United States From 2001 to 2015 in a Privately Insured Population , 2020, Annals of Internal Medicine.

[2]  J. Reimer,et al.  Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care. , 2020, Journal of pharmacological sciences.

[3]  A. Fabbri,et al.  Role of Inhaled Methoxyflurane in the Management of Acute Trauma Pain , 2020, Journal of pain research.

[4]  R. Rauck,et al.  Buprenorphine buccal film for chronic pain management. , 2020, Pain management.

[5]  J. Fudin,et al.  A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain , 2020, Pain and Therapy.

[6]  Chelsea E. Hawley,et al.  Opioid Management in Older Adults with Chronic Kidney Disease: A Review. , 2019, The American journal of medicine.

[7]  E. Bruera,et al.  Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper. , 2019, Journal of pain and symptom management.

[8]  S. Laurent,et al.  Practical management of opioid rotation and equianalgesia , 2018, Journal of pain research.

[9]  P. Hoskin,et al.  Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  A. Caraceni,et al.  Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients , 2018, Cancers.

[11]  F. Heid,et al.  Opioid Rotation in Cancer Pain Treatment. , 2018, Deutsches Arzteblatt international.

[12]  A. Lembke,et al.  Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period , 2018, Pain medicine.

[13]  M. Rech,et al.  When to Pick the Nose: Out‐of‐Hospital and Emergency Department Intranasal Administration of Medications , 2017, Annals of emergency medicine.

[14]  Vittal R. Nagar,et al.  Opioid Use in Chronic Pain Patients with Chronic Kidney Disease: A Systematic Review , 2017, Pain medicine.

[15]  K. Weant,et al.  Review of Intranasally Administered Medications for Use in the Emergency Department. , 2017, The Journal of emergency medicine.

[16]  R. Raffa,et al.  Cebranopadol: novel dual opioid/NOP receptor agonist analgesic , 2017, Journal of clinical pharmacy and therapeutics.

[17]  E. Wachman,et al.  Comparison of Neonatal Abstinence Syndrome Manifestations in Preterm Versus Term Opioid-Exposed Infants , 2016, Advances in neonatal care : official journal of the National Association of Neonatal Nurses.

[18]  Elizabeth Chuang,et al.  Pain management strategies for patients on methadone maintenance therapy: a systematic review of the literature , 2016, BMJ Supportive & Palliative Care.

[19]  O. Olivieri,et al.  Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso‐Occlusive Crisis in Sickle Cell Disease , 2016, Pain practice : the official journal of World Institute of Pain.

[20]  Manar H. Jbara,et al.  A new mathematical approach to methadone conversion , 2016, Journal of pharmacology & pharmacotherapeutics.

[21]  E. Bruera,et al.  Opioid switching in cancer pain: From the beginning to nowadays. , 2016, Critical reviews in oncology/hematology.

[22]  A. Finn,et al.  Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine , 2016, Pain medicine.

[23]  S. Mercadante Opioid metabolism and clinical aspects. , 2015, European journal of pharmacology.

[24]  M. Corrigan,et al.  Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[25]  S. Mclean,et al.  Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. , 2015, Journal of pain and symptom management.

[26]  K. Kulig,et al.  Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors , 2015, Expert opinion on investigational drugs.

[27]  F. Paoletti,et al.  Italian Intersociety Recommendations on pain management in the emergency setting (SIAARTI, SIMEU, SIS 118, AISD, SIARED, SICUT, IRC). , 2015, Minerva anestesiologica.

[28]  H. Sachs The Transfer of Drugs and Therapeutics Into Human Breast Milk: An Update on Selected Topics , 2013, Pediatrics.

[29]  P. Schofield,et al.  Guidance on the management of pain in older people. , 2013, Age and ageing.

[30]  G. Badger,et al.  Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. , 2012, Addiction.

[31]  P. Stone,et al.  Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. , 2012, The Lancet. Oncology.

[32]  Y. Daali,et al.  Analgesics in Patients with Hepatic Impairment , 2012, Drugs.

[33]  A. Somogyi,et al.  Acute Pain Management in Opioid-Tolerant Patients: A Growing Challenge , 2011, Anaesthesia and intensive care.

[34]  Albert Dahan,et al.  Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile , 2010, Pain practice : the official journal of World Institute of Pain.

[35]  F. Roila,et al.  Management of cancer pain: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  G. Hans,et al.  Opioid Rotation in the Management of Chronic Pain: Where Is the Evidence? , 2010, Pain practice : the official journal of World Institute of Pain.

[37]  A. Falcão,et al.  Intranasal drug delivery: how, why and what for? , 2009, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[38]  J. Raeder,et al.  A Comparison of Intravenous Oxycodone and Intravenous Morphine in Patient-Controlled Postoperative Analgesia After Laparoscopic Hysterectomy , 2009, Anesthesia and analgesia.

[39]  R. Portenoy,et al.  Establishing "best practices" for opioid rotation: conclusions of an expert panel. , 2009, Journal of pain and symptom management.

[40]  S. Mercadante,et al.  Equipotent doses to switch from high doses of opioids to transdermal buprenorphine , 2009, Supportive Care in Cancer.

[41]  S. Mercadante,et al.  Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. , 2009, Journal of pain and symptom management.

[42]  R. Cohen Fentanyl Transdermal Analgesia During Pregnancy and Lactation , 2009, Journal of human lactation : official journal of International Lactation Consultant Association.

[43]  L. Ståhle,et al.  Transfer of Buprenorphine Into Breast Milk and Calculation of Infant Drug Dose , 2009, Journal of human lactation : official journal of International Lactation Consultant Association.

[44]  R. Upton,et al.  Pharmacokinetics and Pharmacodynamics of Intranasal Versus Intravenous Fentanyl in Patients with Pain after Oral Surgery , 2008, The Annals of pharmacotherapy.

[45]  A. Williamson,et al.  Management of acute pain in methadone maintenance therapy in-patients. , 2008, Drug and alcohol review.

[46]  A. Dahan,et al.  Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone) , 2008, Pain practice : the official journal of World Institute of Pain.

[47]  L. Illum,et al.  Intranasal delivery: physicochemical and therapeutic aspects. , 2007, International journal of pharmaceutics.

[48]  R. Walsky,et al.  Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6 , 2006, Journal of clinical pharmacology.

[49]  J. Vender,et al.  Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk , 2006, Clinical pharmacology and therapeutics.

[50]  E. Bruera,et al.  Opioid switching: a systematic and critical review. , 2006, Cancer treatment reviews.

[51]  M. Danhof,et al.  Buprenorphine induces ceiling in respiratory depression but not in analgesia. , 2006, British journal of anaesthesia.

[52]  D. Alford,et al.  Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy , 2006, Annals of Internal Medicine.

[53]  Alexander Lachmann,et al.  The effects of racemic D,L-methadone and L-methadone in substituted patients--a randomized controlled study. , 2005, Drug and alcohol dependence.

[54]  S. Mercadante,et al.  Addition of a second opioid may improve opioid response in cancer pain: preliminary data , 2004, Supportive Care in Cancer.

[55]  C. Yost,et al.  Functional Inhibition by Methadone of N-Methyl-d-Aspartate Receptors Expressed in Xenopus Oocytes: Stereospecific and Subunit Effects , 2004, Anesthesia and analgesia.

[56]  G. Lauretti,et al.  Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients , 2003, British Journal of Cancer.

[57]  V. Kouloulias,et al.  Long‐term cancer pain management in morphine pre‐treated and opioid naive patients with transdermal fentanyl , 2003, International journal of cancer.

[58]  Hiroshi Baba,et al.  The Role of N-Methyl-d-Aspartate (NMDA) Receptors in Pain: A Review , 2003, Anesthesia and analgesia.

[59]  W. Ling,et al.  The Clinical Opiate Withdrawal Scale (COWS) , 2003, Journal of psychoactive drugs.

[60]  C. Sessler,et al.  The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. , 2002, American journal of respiratory and critical care medicine.

[61]  P. McNamara Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care , 2002, Palliative medicine.

[62]  A. Vigano,et al.  Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. , 2001, Journal of pain and symptom management.

[63]  F. Fulfaro,et al.  Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  K. Turner,et al.  The rediscovery of methadone for cancer pain management , 2001, The Medical journal of Australia.

[65]  E. Bruera,et al.  Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  E. Kalso,et al.  Controlled-release oxycodone and morphine in cancer related pain , 1997, Pain.

[67]  N. Hagen,et al.  Comparative clinical efficacy and safety of a novel controlled‐release oxycodone formulation and controlled‐release hydromorphone in the treatment of cancer pain , 1997, Cancer.

[68]  W. Paton,et al.  The action of morphine and related substances on contraction and on acetylcholine output of coaxially stimulated guinea‐pig ileum , 1997, British journal of pharmacology.

[69]  M. Tryba,et al.  Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain , 1996, Pain.

[70]  E. Kalso,et al.  Morphine and oxycodone hydrochloride in the management of cancer pain , 1990, Clinical pharmacology and therapeutics.

[71]  R. Houde,et al.  A dinical eomparison of the analgesie effects of methadone and morphine administered intramuseularly, and oforally and parenterally administered methadone , 1967, Clinical pharmacology and therapeutics.

[72]  Sarah Reece-Stremtan,et al.  ABM Clinical Protocol #15: Analgesia and Anesthesia for the Breastfeeding Mother, Revised 2017. , 2017, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.

[73]  H. Ding,et al.  Central N/OFQ-NOP Receptor System in Pain Modulation. , 2016, Advances in pharmacology.

[74]  N. Magrini,et al.  WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses , 2012 .

[75]  S. Schug,et al.  Formulations of Fentanyl for the Management of Pain , 2012, Drugs.

[76]  J. Lötsch,et al.  Pharmacokinetics of Non-Intravenous Formulations of Fentanyl , 2012, Clinical Pharmacokinetics.

[77]  Takako Miyoshi,et al.  Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. , 2009, Journal of pharmacological sciences.

[78]  R. Portenoy,et al.  Opioid rotation: the science and the limitations of the equianalgesic dose table. , 2009, Journal of pain and symptom management.

[79]  S. Datta,et al.  Opioid pharmacology. , 2008, Pain physician.

[80]  M. Moretti Drugs during Pregnancy and Lactation, 2nd edition , 2008 .

[81]  M. Fallon Principles of opioid titration , 2007 .

[82]  R. D. du Bois,et al.  No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. , 2006, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[83]  C. Quigley,et al.  Opioid switching to improve pain relief and drug tolerability. , 2004, The Cochrane database of systematic reviews.

[84]  T. Buclin,et al.  Interindividual Variability of the Clinical Pharmacokinetics of Methadone , 2002, Clinical pharmacokinetics.

[85]  A. Miller,et al.  A RANDOMISED CROSSOVER COMPARISON OF CONTROLLED RELEASE HYDROMORPHONE TABLETS WITH CONTROLLED RELEASE MORPHINE TABLETS IN PATIENTS WITH CANCER PAIN , 1999 .